Cancer Chemotherapy and Pharmacology

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer
Cancer Chemotherapy and Pharmacology - Tập 69 Số 6 - Trang 1529-1536 - 2012
Asakuma, Maiko, Yamamoto, Michiko, Wada, Mayuko, Ryuge, Shinichiro, Katono, Ken, Yokoba, Masanori, Fukui, Tomoya, Takakura, Akira, Otani, Sakiko, Maki, Sachiyo, Igawa, Satoshi, Yanaihara, Tomoko, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Masuda, Noriyuki
We conducted a phase I trial of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with amrubicin, a topoisomerase II inhibitor, with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support to overcome the neutropenia associated with this particular combination. The aim was to determine the maximum tolerated dose (MTD) of amrubicin combined with a fixed dose of CPT-11 and... hiện toàn bộ
Adjuvant chemotherapy with early intravesical instillation of Adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer
Cancer Chemotherapy and Pharmacology - Tập 30 Số S1 - Trang S31-S36 - 1992
Toshihisa Ueda, Seiji Naito, Atsushi Iguchi, Kazuyuki Saito, Yoshihito Osada, Asami Ariyoshi, Tetsuo Omoto, Joichi Kumazawa
The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer
Cancer Chemotherapy and Pharmacology - Tập 67 - Trang 103-110 - 2010
M. F. Ullah, H. Y. Khan, H. Zubair, U. Shamim, S. M. Hadi
Ascorbic acid is an essential micronutrient and is considered to have an antioxidant function in living systems. For the past several decades, ascorbic acid has been the subject of considerable interest as an anticancer agent. Several studies have shown that ascorbic acid is cytotoxic to a variety of cancer cells, whereas normal cells are relatively resistant to such cytotoxic action. In this stud... hiện toàn bộ
Erratum: Cancer Chemother Pharmacol (1999) 43: 1–7
Cancer Chemotherapy and Pharmacology - Tập 43 - Trang 524-524 - 1999
Evaluation of multidisciplinary treatment of bladder cancer, especially in chemoimmunotherapy (ADM and OK-432) as a consolidation therapy
Cancer Chemotherapy and Pharmacology - Tập 11 - Trang S47-S50 - 1983
Yoshizo Nakagami, Tatsuo Minowa, Kazuhiko Tozuka, Yasunori Hiraoka, Hansui Chin
The relapse rate of bladder cancer (transitional cell Ca) is said to be about 45%–80% even after tumor resection. Multidisciplinary treatment was designed and studied to prevent such recurrence. This treatment was designed to have three steps: induction, consolidation, and maintenance therapy. Following surgical tumor removal, OK-432 and Adriamycin (ADM) were administered as consolidation therapy,... hiện toàn bộ
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
Cancer Chemotherapy and Pharmacology - Tập 31 - Trang 229-239 - 1992
Peter J. Houghton, Pamela J. Cheshire, Leann Myers, Clinton F. Stewart, Timothy W. Synold, Janet A. Houghton
The topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) was evaluated against a panel of xenografts comprising four lines of adult colon adenocarcinoma, three colon tumors derived from adolescents, six childhood rhabdomyosarcomas from previously untreated patients as well as sublines selected in vivo for resistance to vincristine and melphalan, and three lines of chi... hiện toàn bộ
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma
Cancer Chemotherapy and Pharmacology - Tập 45 - Trang 495-501 - 2000
Luca Fumagalli, Massimo Zucchetti, Idria Parisi, Maria Grazia Viganò, Bruno Zecca, Anna Careddu, Maurizio D'Incalci, Adriano Lazzarin
Purpose: To investigate the pharmacokinetics of liposomal daunorubicin (DaunoXome) administered alone or in combination with antiviral therapy including protease inhibitors (PI) to HIV-positive patients affected by Kaposi's sarcoma (KS). Patients and methods: A group of 18 patients with extensive or rapidly progressing AIDS-related KS received DaunoXome at a dose of 40 mg/m2 alone or in associatio... hiện toàn bộ
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
Cancer Chemotherapy and Pharmacology - - 2023
Danielle Shafer, Amanda B. Kagan, Michelle A. Rudek, Maciej Kmieciak, Mary Beth Tombes, Ellen Shrader, Dipankar Bandyopadhyay, Daniel S. Hudson, Heidi Sankala, Caryn Weir, Jeffrey E. Lancet, Steven Grant
New cancer chemotherapy drugs in Europe
Cancer Chemotherapy and Pharmacology - Tập 1 - Trang 5-13 - 1978
G. Mathé, L. M. van Putten
Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology - Tập 24 - Trang 102-104 - 1989
Shan D. Chetiyawardana, Michael H. Cullen, Ramesh C. Joshi, Charlotte M. Woodroffe
Ifosfamide and mitomycin C are two of the more active single agents in non-small-cell lung cancer (NSCLC). This study evaluates these drugs in combination followed by radiotherapy. A total of 33 ambulatory patients with inoperable NSCLC were treated with 5 g/m2 ifosfamide as a 24-h infusion, with the concurrent administration of sodium 2-mercaptoethane sulphonate (mesna; 160% of the ifosfamide dos... hiện toàn bộ
Tổng số: 6,166   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10